NewsMeter
Zero unexpected in-life adverse findings across 162 rats in a repeat 13-week study removes the primary obstacle for NMRA-215, Neumora Therapeutics' (Nasdaq: NMRA) oral NLRP3 inhibitor targeting obesity and cardiometabolic disease.
company disclosed the results in a July 27, 2026 8-K filing, attributed the prior adverse findings to study-conduct discrepancies rather than the compound, and said it plans to submit an investigational new drug application in the fourth quarter of 2026, with a Phase 1 study start targeted before year-end.
The problem the repeat study was designed to fix The prior 13-week rat study recorded unexpected in-life adverse findings in 5 of 142 animals. That count triggered a for-cause audit.
The audit identified various discrepancies and returned a number of critical observations about how that original study was conducted.
Keep reading